1159490-85-3

Basic information

• Product Name: PF-04217903
• Synonyms: PF-04217903;4-[1-(6-Quinolinylmethyl)-1H-1,2,3-triazolo[4,5-b]pyrazin-6-yl]-1H-pyrazole-1-ethanol 4-hydroxybenzenesulfonate;aka PF-04217903;PF04217903 4-hydroxybenzenesulfonate
• CAS NO: 1159490-85-3
• Molecular Formula: C25H22N8O5S
• Molecular Weight: 546.55778
• EINECS: -0
• Mol File: 1159490-85-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: PF-04217903(CAS DataBase Reference)
• NIST Chemistry Reference: PF-04217903(1159490-85-3)
• EPA Substance Registry System: PF-04217903(1159490-85-3)

Safety Data

• Hazardous Substances Data: 1159490-85-3(Hazardous Substances Data)

Usage

Description

PF-04217903 is a small molecule inhibitor specifically designed for the treatment of various forms of cancer. It functions by targeting and inhibiting the focal adhesion kinase (FAK), a protein integral to cancer cell survival and dissemination. PF-04217903's ability to curb tumor growth and metastasis positions it as a promising candidate for cancer therapy.
Used in Pharmaceutical Industry:
PF-04217903 is used as an anti-cancer agent for its capacity to inhibit the activity of the focal adhesion kinase (FAK), which is crucial in cancer cell survival and spread. This inhibition has been shown to suppress tumor growth and metastasis, making it a potential therapeutic intervention for cancer patients.
Used in Cancer Therapy:
PF-04217903 is used as a therapeutic agent for its potential to treat various forms of cancer by targeting the FAK pathway, thereby disrupting the mechanisms that allow cancer cells to proliferate and invade surrounding tissues.
Used in Research Applications:
PF-04217903 is used as a research tool for studying the role of FAK in cancer progression and metastasis, providing insights into the development of targeted cancer therapies.
Used in Idiopathic Pulmonary Fibrosis Treatment:
PF-04217903 is being investigated as a potential treatment for idiopathic pulmonary fibrosis, leveraging its ability to target FAK, which may be implicated in the pathogenesis of this condition.
Used in Rheumatoid Arthritis Treatment:
PF-04217903 is also being explored for its potential in treating rheumatoid arthritis, where its FAK-inhibiting properties could help manage inflammation and joint damage associated with the disease.